WT1 expression

sequential monitoring of WT1 gene expression in intermediate- or high-risk AML patients after allo-HSCT within 3 years, with timely preemptive therapy for those who become WT1-positive, can effectively reduce relapse and improve prognosis. A WT1 gene expression level of 120 copies may be a more precise and reliable intervention threshold for preemptive therapy.

P1/2, N=20, Completed, Sellas Life Sciences Group | Unknown status --> Completed | Phase classification: PN/A --> P1/2

P1, N=29, Terminated, Pyramid Biosciences | Phase classification: P1/2 --> P1

P1/2, N=29, Terminated, Pyramid Biosciences | N=74 --> 29 | Trial completion date: Jun 2024 --> Jul 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2024 --> Jul 2023; Sponsor terminated development of PBI-200

The resection specimen was comprised of ~55% and ~45% stromal and epithelial elements, respectively, with no anaplasia, but immunohistochemistry using AFP staining revealed positive mucinous intestinal epithelium, consistent with the serum AFP observations. The lack of correlation between tumor response and serum AFP levels in this case highlights a more general clinical unmet need to identify WT-specific circulating tumor markers.

The augmented avidity conferred by the binding of two anti-WT1-HLA-A*02:01 Fab arms has only minimal influence on cell killing potency. These findings demonstrate the need for careful examination of key design parameters for the development of next-generation T cell engagers targeting low density TAA-pMHCs on tumor cells.

It can be utilized as an auxiliary diagnostic indicator for classical MPN staging but is not correlated with the incidence of thrombotic events. Male and positive JAK2 gene mutation are risk factors for thrombotic events in ET patients.

The selinexor-containing regimens used in this study were either selinexor (35mg/m 2 biw) alone or in combination with other drugs (decitabine, azacytidine, venetoclax, low-dose cytarabine, and CAG (cytarabine, aclarubicin, G-CSF) regimen). Selinexor-containing regimens have been shown to be effective and well tolerated in post-transplant AML/MDS patients with MRD-positive, including those who have failed first-line preemptive treatment.

P1/2, N=74, Active, not recruiting, Pyramid Biosciences | Recruiting --> Active, not recruiting

P1, N=15, Active, not recruiting, 3D Medicines | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2023 --> May 2024

In conclusion, the availability of comprehensive kidney morphology and single-cell transcriptome atlas at various developmental stages of C57BL/6 mice would be a new and significant resource for mechanistic investigations and testing of potential therapeutic interventions.